Critical appraisal:Passlick B, Kubuschock B, Sienel W, Thetter O, Pantel K, Izbicki JR 2002 3

From Cancer Guidelines Wiki
Jump to: navigation, search

Critical Appraisal

Article being appraised

Passlick B, Kubuschock B, Sienel W, Thetter O, Pantel K, Izbicki JR. Mediastinal lymphadenectomy in non-small cell lung cancer: effectiveness in patients with or without nodal micrometastases - results of a preliminary study. Eur J Cardiothorac Surg 2002 Mar;21(3):520-6 [Abstract available at http://www.ncbi.nlm.nih.gov/pubmed/11888774].


Applicable clinical question

What is the clinical benefit of mediastinal lymph node dissection in stage IIIA operable NSCLC?

Key Facts

Study Design

randomised controlled trial

Number of Patients:

201

Includes an economic evaluation

no

Evidence ratings

Level of evidence

II

Quality of evidence
High Additional comments: Well designed RCT.


Size of effect
2 Reason for decision: The point estimate of effect is clinically important BUT the confidence interval includes clinically unimportant effects.
Relevance of evidence
1 Additional comments: Evidence of an effect on patient‐relevant clinical outcomes including benefits and harms, and survival.
Result of appraisal

Jutta's tick icon.png Included




Completed by

Associate Professor Gavin Wright MD FRACS


Jutta's tick icon.png This appraisal has been completed.
Article
Passlick B, Kubuschock B, Sienel W, Thetter O, Pantel K, Izbicki JR. Mediastinal lymphadenectomy in non-small cell lung cancer: effectiveness in patients with or without nodal micrometastases - results of a preliminary study. Eur J Cardiothorac Surg 2002 Mar;21(3):520-6 [Abstract available at http://www.ncbi.nlm.nih.gov/pubmed/11888774].
Assigned to
User:Gavin.wright
Topic area
Guidelines:Lung cancer/Treatment/Non-small-cell stage III operable
Clinical question
What is the clinical benefit of mediastinal lymph node dissection in stage IIIA operable NSCLC?


Section below only relevant for Cancer Council Project Officer

Edit appraisal assignment